BioSpace News Archive

Inhibikase Therapeutics, Inc. announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S. markets.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in the following upcoming investor conferences.

Oryzon Genomics, S.A. announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder.

Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies, announced its participation at two upcoming investor conferences.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

Cue Biopharma, Inc. announced that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.

Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in three upcoming investor conferences in November.

VYNE Therapeutics Inc. today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m. ET.

Corbus Pharmaceuticals Holdings, Inc. today provided a corporate update and reported financial results for the third quarter of 2023.